• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Transfusion Transmission of Hepatitis A Virus during a Recent Epidemic in Europe

February 21, 2023

In most infections of hepatitis A (HAV), individuals have very mild symptoms or are asymptomatic.  Although rare in the U.S., globally HAV causes about 1.4 million cases and usually spreads via fecal-oral routes; however, case reports have documented transmission by sexual contact and transfusion.  An HAV outbreak occurred in Europe from 2016 to 2019, and researchers detected a rising number of HAV cases in Poland between mid-2017 and 2019.  To better understand the transfusion-transmission potential of HAV, researchers in Poland screened 1,866,590 blood donations from 1,210,423 donors in mini-pools for HAV between 2017 to 2019.  During the outbreak, 28 HAV positive blood donations from 21 donors were identified (n=13 donors from 2017, n=6 from 2018, and n=2 from 2019).  A total of 54 HAV positive blood components were prepared, and 37 units were transfused (23/27 HAV positive RBC units, 13/27 platelets, and 1/28 plasma units).  Of the 12 HAV positive blood components that were traced after transfusion to seven patients, two cases of transfusion-transmitted HAV were identified (28.6%)—one asymptomatic and one symptomatic infection.  Follow-up samples from 20-HAV infected donors revealed HAV-RNA persisted for a maximum of 125 days.  Based on these results and the identification of a HAV reactive donor after vaccination, a 6-month donor deferral after HAV infection and 14 days post HAV vaccination may be prudent to protect patients from HAV transfusion-transmission.

Reference:

Sulkowska E, Masny A, Kalińska A, Kopacz A, Kubicka-Russel D, Marek M, Parczewski M, Radłowski D, Jaroszewicz J, Trzcińska A, Łetowska M, Grabarczyk P; Group of Polish Blood Transfusion Centers for blood borne pathogens. Hepatitis A virus (HAV) RNA detection in Polish blood donors and likely transmissions through blood components during the 2017-2019 epidemic. Transfusion. 2023 Feb;63(2):349-359.

 

Filed Under

  • News
  • Transfusion Transmitted Infections

Recommended

  • mRNA-1273 Vaccine Safe and Induces anti-SARS-CoV-2 Immune Responses

  • Blood Donation Intervals Should Be Extended to 180 Days To Avoid Iron Deficiency

  • Perfluoroalkyl and Polyfluoroalkyl Levels after Blood Donations

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Array-based, comprehensive genotyping for erythroid, platelet, neutrophil and leukocyte antigens

  • Acute Normovolemic Hemodilution Does Not Reduce RBC Transfusions

  • Blood Donation Teams—a Novel Strategy to Support Novice Donors

  • Plasma Exchange to Reduce Biological Age

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley